Jefferies Financial Group Cuts Moderna (NASDAQ:MRNA) Price Target to $55.00

Moderna (NASDAQ:MRNA) had its target price decreased by Jefferies Financial Group from $65.00 to $55.00 in a research report report published on Tuesday, Benzinga reports. Jefferies Financial Group currently has a hold rating on the stock.

MRNA has been the subject of a number of other reports. TD Cowen reduced their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Friday, September 13th. Bank of America lowered their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. Finally, The Goldman Sachs Group decreased their price target on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $97.18.

Moderna Stock Down 4.6 %

Shares of Moderna stock opened at $54.82 on Tuesday. The stock has a market capitalization of $21.01 billion, a price-to-earnings ratio of -3.50 and a beta of 1.66. Moderna has a twelve month low of $54.82 and a twelve month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The business’s 50 day simple moving average is $71.36 and its 200-day simple moving average is $104.92.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period last year, the company earned ($3.62) earnings per share. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. Equities research analysts forecast that Moderna will post -9.85 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,184 shares of company stock worth $3,804,931 in the last ninety days. 15.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MRNA. Vanguard Group Inc. boosted its stake in Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after purchasing an additional 5,129,800 shares during the period. Capital World Investors boosted its position in shares of Moderna by 0.5% in the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after buying an additional 18,728 shares during the period. Mawer Investment Management Ltd. grew its holdings in shares of Moderna by 6.7% during the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after buying an additional 120,621 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after buying an additional 463,960 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Moderna by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after buying an additional 29,566 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.